Physician profile
Eric D Thomas
NPI 1881915940
$3,413.72
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $100 · 2022: $792 · 2023: $784 · 2024: $1,202 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $89.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.62 |
| Education | $89.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,215.99 | 2023-2025 | Tisseel, Perclot, Seprafilm |
| Astrazeneca Pharmaceuticals Lp | $308.61 | 2019-2024 | Lynparza |
| Pacira Pharmaceuticals Incorporated | $247.11 | 2023 | Exparel |
| Intuitive Surgical, INC. | $207.38 | 2022 | |
| Glaxosmithkline, LLC. | $182.57 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $174.41 | 2019 | |
| Avanos Medical | $146.24 | 2022 | |
| Clovis Oncology, INC. | $138.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $134.68 | 2019-2024 | |
| Genmab U.S., INC. | $124.55 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.81 | 2023 | Libtayo |
| Abbvie INC. | $115.25 | 2024 | |
| Veran Medical Technologies, INC. | $83.99 | 2020 | |
| Axonics, INC. | $54.36 | 2022 | |
| Genzyme Corporation | $48.71 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.93 | 2024 | Veozah |
| Conmed Corporation | $28.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.34 | 2024 | |
| Merck Sharp & Dohme LLC | $17.41 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.95 | 2025 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.